15890 Federal Register / Vol. 72, No. 63 / Tuesday, April 3, 2007 / Notices 

Dated: March 27, 2007. 

Alexandra Huttinger, 

Acting Director, Division of Policy Review 

and Coordination. 

[FR Doc. E7–6089 Filed 4–2–07; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908), 

on September 30, 1997 (62 FR 51118), 

and on April 13, 2004 (69 FR 19644). 

A notice listing all currently certified 

laboratories is published in the Federal 

Register during the first week of each 

month. If any laboratory’s certification 

is suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end, 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http://workplace.samhsa.gov 

and http://www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh or Dr. Walter Vogl, 

Division of Workplace Programs, 

SAMHSA/CSAP, Room 2–1035, 1 Choke 

Cherry Road, Rockville, Maryland 

20857; 240–276–2600 (voice), 240–276–

2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Public Law 

100–71. Subpart C of the Mandatory 

Guidelines, ‘‘Certification of 

Laboratories Engaged in Urine Drug 

Testing for Federal Agencies,’’ sets strict 

standards that laboratories must meet in 

order to conduct drug and specimen 

validity tests on urine specimens for 

Federal agencies. To become certified, 

an applicant laboratory must undergo 

three rounds of performance testing plus 

an on-site inspection. To maintain that 

certification, a laboratory must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories which claim to be in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A laboratory 

must have its letter of certification from 

HHS/SAMHSA (formerly: HHS/NIDA) 

which attests that it has met minimum 

standards. 

In accordance with Subpart C of the 

Mandatory Guidelines dated April 13, 

2004 (69 FR 19644), the following 

laboratories meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328–

7840/800–877–7016, (Formerly: 

Bayshore Clinical Laboratory). 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264. 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770/888–290–

1150. 

Aegis Analytical Laboratories, Inc., 345 

Hill Ave., Nashville, TN 37210, 615–

255–2400. 

Baptist Medical Center-Toxicology 

Laboratory, 9601 I–630, Exit 7, Little 

Rock, AR 72205–7299, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800–

445–6917. 

Diagnostic Services, Inc., dba DSI, 

12700 Westlinks Drive, Fort Myers, 

FL 33913, 239–561–8200/800–735–

5416. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602, 229–671–

2281. 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974, 

215–674–9310. 

Dynacare Kasper Medical Laboratories,*

10150–102 St., Suite 200, Edmonton, 

Alberta, Canada T5J 5E2, 780–451–

3702/800–661–9876. 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662–

236–2609. 

Gamma-Dynacare Medical 

Laboratories,* A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519–

679–1630. 

Kroll Laboratory Specialists, Inc., 1111 

Newton St., Gretna, LA 70053, 504–

361–8989/800–433–3823, (Formerly: 

Laboratory Specialists, Inc.). 

Kroll Scientific Testing Laboratories, 

Inc., 450 Southlake Blvd., Richmond, 

VA 23236, 804–378–9130, (Formerly: 

Scientific Testing Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984. 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group). 

Laboratory Corporation of America 

Holdings, 10788 Roselle St., San 

Diego, CA 92121, 800–882–7272, 

(Formerly: Poisonlab, Inc.). 

Laboratory Corporation of America 

Holdings, 550 17th Ave., Suite 300, 

Seattle, WA 98122, 206–923–7020/ 

800–898–0180. (Formerly: DrugProof, 

Division of Dynacare/Laboratory of 

Pathology, LLC; Laboratory of 

Pathology of Seattle, Inc.; DrugProof, 

Division of Laboratory of Pathology of 

Seattle, Inc.). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339, (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845, 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.). 

Marshfield Laboratories, Forensic 

Toxicology Laboratory, 1000 North 

Oak Ave., Marshfield, WI 54449, 715–

389–3734/800–331–3734. 

MAXXAM Analytics Inc.,* 6740 

Campobello Road, Mississauga, ON, 

Canada L5N 2L8, 905–817–5700, 

(Formerly: NOVAMANN (Ontario), 

Inc.). 


ycherry on PROD1PC64 with NOTICES
Federal Register / Vol. 72, No. 63 / Tuesday, April 3, 2007 / Notices 15891 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244. 

Meriter Laboratories, 36 South Brooks 

St., Madison, WI 53715, 608–267–

6225, (Formerly: General Medical 

Laboratories). 

MetroLab-Legacy Laboratory Services, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725–

2088. 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304, 661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504, 888–747–3774. (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory). 

Oregon Medical Laboratories, 123 

International Way, Springfield, OR 

97477, 541–341–8092. 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942, (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory). 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204, 509–755–8991/ 

800–541–7891x7. 

Physicians Reference Laboratory, 7800 

West 110th St., Overland Park, KS 

66210, 913–339–0372/800–821–3627. 

Quest Diagnostics Incorporated, 3175 

Presidential Dr., Atlanta, GA 30340, 

770–452–1590/800–729–6432, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 506 E. 

State Pkwy., Schaumburg, IL 60173, 

800–669–6995/847–885–2010, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; International 

Toxicology Laboratories). 

Quest Diagnostics Incorporated, 7600 

Tyrone Ave., Van Nuys, CA 91405, 

866–370–6699/818–989–2521, 

(Formerly: SmithKline Beecham 

Clinical Laboratories). 

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109, 505–

727–6300/800–999–5227. 

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, 

IN 46601, 574–234–4176 x276. 

Southwest Laboratories, 4645 E. Cotton 

Center Boulevard, Suite 177, Phoenix, 

AZ 85040, 602–438–8507/800–279–

0027. 

Sparrow Health System, Toxicology 

Testing Center, St. Lawrence Campus, 

1210 W. Saginaw, Lansing, MI 48915, 

517–364–7400, (Formerly: St. 

Lawrence Hospital & Healthcare 

System). 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., 

Oklahoma City, OK 73101, 405–272–

7052. 

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 

70 West, Suite 208, Columbia, MO 

65203, 573–882–1273. 

Toxicology Testing Service, Inc., 5426 

N.W. 79th Ave., Miami, FL 33166, 

305–593–2260. 

U.S. Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755–

5235, 301–677–7085. 

The following laboratory withdrew 

from the NLCP on March 31, 2007: 

Quest Diagnostics Incorporated, 4230 

South Burnham Ave., Suite 250, Las 

Vegas, NV 89119–5412, 702–733–

7866/800–433–2750, (Formerly: 

Associated Pathologists Laboratories, 

Inc.). 

*The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on April 13, 2004 (69 FR 

19644). After receiving DOT 

certification, the laboratory will be 

included in the monthly list of HHScertified laboratories and participate in 

the NLCP certification maintenance 

program. 

Dated: March 27, 2007. 

Elaine Parry, 

Acting Director, Office Program Services, 

SAMHSA. 

[FR Doc. E7–6119 Filed 4–2–07; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Bureau of Customs and Border 

Protection 

Proposed Collection; Comment 

Request; U.S./Israel Free Trade 

Agreement 

ACTION: Notice and request for 

comments. 

SUMMARY: As part of its continuing effort 

to reduce paperwork and respondent 

burden, Customs and Border Protection 

(CBP) invites the general public and 

other Federal agencies to comment on 

an information collection requirement 

concerning the U.S./Israel Free Trade 

Agreement. This request for comment is 

being made pursuant to the Paperwork 

Reduction Act of 1995 (Pub. L. 104–13; 

44 U.S.C. 3505(c)(2)). 

DATES: Written comments should be 

received on or before June 4, 2007, to be 

assured of consideration. 

ADDRESSES: Direct all written comments 

to U.S. Customs Service, Information 

Services Group, Room 3.2C, Attn.: 

Tracey Denning, 1300 Pennsylvania 

Avenue, NW., Washington, DC 20229. 

FOR FURTHER INFORMATION CONTACT: 

Requests for additional information 

should be directed to U.S. Customs 

Service, Attn.: Tracey Denning, Room 

3.2C, 1300 Pennsylvania Avenue, NW., 

Washington, DC 20229, Tel. (202) 344–

1429. 

SUPPLEMENTARY INFORMATION: CBP 

invites the general public and other 

Federal agencies to comment on 

proposed and/or continuing information 

collections pursuant to the Paperwork 

Reduction Act of 1995 (Pub. L. 104–13; 

44 U.S.C. 3505(c)(2)). The comments 

should address: (a) Whether the 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimates of the burden of the 

collection of information; (c) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; (d) 

ways to minimize the burden including 

the use of automated collection 

techniques or the use of other forms of 

information technology; and (e) 


ycherry on PROD1PC64 with NOTICES